How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? Eli Lilly ...

Novo Nordisk A/S aims to start selling its weight-loss blockbuster Wegovy in vials, its latest move to win over customers ...

Eli Lilly and Company (NYSE:LLY) is included among 13 Best Long Term Low Risk Stocks to Buy Now. On February 5, Goldman Sachs ...

The investment supports Eli Lilly and Company’s $3.5 billion expansion into Upper Macungie Township, marking the largest ...

Eli Lilly and Company (NYSE:LLY) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Eli Lilly and Company (NYSE:LLY) announced an agreement to acquire Orna Therapeutics in a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… ...

Eli Lilly is flying high thanks to its success in the GLP-1 space, but what comes next?

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Novo Nordisk just did Eli Lilly stock a huge favor.

It’s become clear that Big Pharma is not a friend of ordinary Americans. Prices are too high and have been rising for too ...

Combined sales for the company's blockbuster GLP-1 drugs Zepbound and Mounjaro exceeded $1 billion, with each showing ...